Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Peggy Lum"'
Publikováno v:
The Journal of Clinical Pharmacology. 46:747-757
This analysis was conducted to characterize the pharmacokinetics and pharmacodynamics of pegfilgrastim and to develop a pharmacokinetic-pharmacodynamic model to describe the granulopoietic effects of pegfilgrastim and the homeostatic regulation of pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba019cec1c36f0e1ebc4ca93b8d3a4c6
https://doi.org/10.1177/0091270006288731
https://doi.org/10.1177/0091270006288731
Autor:
Rosalin Arends, Peggy Lum, Juan Jose Perez Ruixo, Alin Chen, Lorin Roskos, Brian Smith, Bing-Bing Yang
Publikováno v:
Clinical pharmacokinetics. 49(11)
Panitumumab is a recombinant, fully human IgG2 monoclonal antibody directed against the epidermal growth factor receptor (EGFR). It is indicated for use as monotherapy in the treatment of patients with EGFR-expressing metastatic colorectal cancer aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46388ed509f0f382aad9e0ec3a26e1b3
https://pubmed.ncbi.nlm.nih.gov/20923247
https://pubmed.ncbi.nlm.nih.gov/20923247
Autor:
Allen Lee Cohn, Howard A. Burris, Roger B. Cohen, Peggy Lum, Timothy G. Larson, Rafael G. Amado, Xinqun Yang, Udit Verma, Jeffrey Crawford, Charles Gregory, Julie C. Martin, Joe Stephenson
Publikováno v:
Clinical colorectal cancer. 8(1)
Purpose This study evaluated safety, pharmacokinetics, and efficacy of 2 dose schedules and 2 infusion times of panitumumab in patients with advanced solid malignancies. Patients and Methods This phase I multicenter, openlabel study sequentially enro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc5b06e2cb837ddd37360e745a8e4e7d
https://pubmed.ncbi.nlm.nih.gov/19203894
https://pubmed.ncbi.nlm.nih.gov/19203894
Autor:
David A. Brenner, Stefan Zahn, Claudia Hirth-Dietrich, Myung-Sam Cho, Paul Ng, Roopa Ramamoorthi, Greg Roldan, Clark Pan, Andreas Knorr, Baisong Mei, Nikki Feirt, Blair U. Bradford, Peggy Lum, Barbara Krebs, Adrian Tomkinson, Bodo Brocks, Ellen Cheung, Sabine Kraft, Michael Schauer, Christopher J. Parsons
Publikováno v:
Hepatology (Baltimore, Md.). 40(5)
Liver fibrosis is characterized by increased synthesis, and decreased degradation, of extracellular matrix (ECM) within the injured tissue. Decreased ECM degradation results, in part, from increased expression of tissue inhibitor of metalloproteinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204e19c058cfdae82581260583d1316f
https://pubmed.ncbi.nlm.nih.gov/15389776
https://pubmed.ncbi.nlm.nih.gov/15389776
Publikováno v:
Journal of pharmaceutical sciences. 93(5)
This report provides the evidence that pegfilgrastim, which is produced by covalently binding a 20-kDa polyethylene glycol molecule to filgrastim, has decreased renal clearance compared with the native protein, filgrastim. After intravenous administr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe52f2b797aa8cd91281529c0bae5fa
https://pubmed.ncbi.nlm.nih.gov/15067712
https://pubmed.ncbi.nlm.nih.gov/15067712
Autor:
Bing Bing Yang, Robert Radinsky, Sameer Doshi, Juan Jose Perez Ruixo, Daniel J. Freeman, Peggy Lum, Thore Hettman, Selam Ogbagabriel, Alin Chen
Publikováno v:
Molecular Cancer Therapeutics. 8:B167-B167
Background: HER3 is a member of the Human Epidermal Growth Factor Receptor (HER) family. Although HER3 lacks intrinsic kinase activity, it serves as a scaffold for PI3K/AKT signaling for the HER family via heterodimeric interactions. The goal of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::737c226a4beab607e8af5912e642dbbd
https://doi.org/10.1158/1535-7163.targ-09-b167
https://doi.org/10.1158/1535-7163.targ-09-b167